Merck (MRK) stock gains as its bestselling drug, Keytruda, as part of a combination regimen, succeeds in a Phase 3 trial for ...

Novel combination achieves 60.8% response rate and 90.2% disease control rate in first-line non-small cell lung cancer (1L ...

Find insight on Merck and Exelixis in the latest Market Talks covering Health Care.

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

PDS Biotechnology Corporation (NASDAQ: PDSB) Q1 2025 Earnings Call Transcript May 14, 2025 PDS Biotechnology Corporation ...

Exelixis delivers a strong Q1 performance with raised 2025 guidance, robust Cabometyx sales, and share buybacks. Read the ...

The Trump administration is already gearing up for another round of Medicare drug price negotiations, while OpenAI launched a ...

As of March 31, 2025, Pyxis Oncology had cash and cash equivalents, including restricted cash, and short-term investments, of $106.9 million. The Company believes that its current cash, cash ...

Biotech investors are preparing for what may be the most important clinical trial readout for them this summer.

The ASX 300 stock highlights that ~92% of all evaluable patients have a programmed death-ligand 1 (PD-L1) Tumor Proportion ...

(Reuters) -The U.S. Food and Drug Administration has approved AbbVie's drug to treat adults with a type of lung cancer who ...

Is there anyone who thinks prescription drug prices in America are about right? President Trump has elevated an issue ...